Erythropoietin Drugs Market Estimated to Reach USD 14.3 billion, Advancing at a CAGR of 3.8% by 2034: Transparency Market Research Inc.
18 sept. 2024 07h05 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The global erythropoietin drugs market is estimated to surge at a CAGR of 3.8% from 2024...
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
12 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Culture Biosciences and Google Cloud Announce Collaboration to Revolutionize Bioprocess Development
10 sept. 2024 10h00 HE
|
Culture Biosciences
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Culture Biosciences—a leader in automated bioprocess development, optimization and data science —announces a strategic...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
09 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160...
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report
05 sept. 2024 06h00 HE
|
FACT.MR
Rockville, MD, Sept. 05, 2024 (GLOBE NEWSWIRE) -- According to a new industry report released by Fact.MR, revenue from the global pseudarthrosis treatment market is estimated to reach US$ 879.4...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
03 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Lifecore Biomedical Announces Chief Financial Officer Transition
29 août 2024 07h00 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
26 août 2024 17h23 HE
|
Lifecore Biomedical, Inc.
-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% ---- High Value Pipeline Continues to Advance Toward Commercialization ---- State-of-the-Art Technology...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
02 juil. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
01 juil. 2024 07h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...